POSB38 Developing a Cost-Effectiveness Analysis for Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in the Absence of Overall Survival Data
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.311
https://www.valueinhealthjournal.com/article/S1098-3015(21)02106-9/fulltext
Title :
POSB38 Developing a Cost-Effectiveness Analysis for Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in the Absence of Overall Survival Data
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02106-9&doi=10.1016/j.jval.2021.11.311
First page :
Section Title :
Open access? :
No
Section Order :
11084